MedTrace Logo

Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment

NCT00902005 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 145

Last updated 2013-11-21

No results posted yet for this study

Summary

The aim of this study is to examine the associations between inflammatory disease activity and endothelial function in rheumatoid arthritis (RA) and spondyloarthritis patients treated with methotrexate and Tumor Necrosis Factor alpha (TNFalpha)inhibitor in combination or methotrexate or TNFalpha-inhibitor alone. Further, to look for improvement in endothelial function, and decrease in bone and cartilage destruction during treatment with the combination therapy of TNFalpha-inhibitor and methotrexate in RA and Psoriatic Arthritis (PSA) patients. Last, examine the TNFalpha inhibitors influence on endothelial function and levels of bone and cartilage markers in patients with Ankylosing Spondylitis (AS).

Conditions

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Revmatismesykehuset AS

    lead OTHER

Principal Investigators

  • Knut Mikkelsen, MD · Lillehammer Hospital for Rheumatic Diseases

  • Gunnbjørg Hjeltnes, MD · Lillehammer Hospital for Rheumatic Diseases

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-06-30
Completion
2012-08-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902005 on ClinicalTrials.gov